Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pharmaceutical Design
  4. Fast Track Articles
  5. Fast Track Article
image of Use of SGLT2 Inhibitors in Frail Older Adults is Associated with Increased Survival: A Retrospective Study

Abstract

Background

In recent years, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a valuable treatment for type 2 diabetes (T2D) and heart failure. Despite these medications seeming to be safe in older people, the literature about SGLT2i and frailty is still limited. This study aims to evaluate whether SGLT2i use is associated with increased survival in older adults and if frailty can affect the findings.

Material and Methods

We enrolled over 65 patients admitted to the Geriatrics Wards at the University Hospital 'P. Giaccone' in Palermo, Italy, between December 2022 and May 2023. After 12 months of follow-up, various outcomes were assessed, including mortality, hospitalization, glycemic dysregulation, urinary tract infections, and falls. The association between SGLT2i use and mortality was analyzed and reported as hazard ratios (HRs) with their 95% confidence intervals (CIs).

Results

A total of 80 patients were included in the study (mean age 79.5 ± 8.5 years; 50% were women). Patients using SGLT2i had a higher prevalence of T2D ( 0.02) and cirrhosis ( 0.001). After adjusting for potential confounders, SGLT2i use was significantly associated with a reduced mortality risk (HR = 0.53; 95% CI: 0.20-0.93; 0.02). When stratified by the presence of multidimensional frailty, SGLT2i use was significantly associated with a lower risk of mortality in frail patients (HR = 0.27; 95% CI: 0.06-0.88; 0.008), but not in robust ones.

Conclusion

In older frail patients, the use of SGLT2i is associated with reduced mortality after 12 months of follow-up. Further larger studies are needed to evaluate the role of these medications in older adults.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128347041241129055001
2025-01-13
2025-04-02

  • From This Site

    /content/journals/cpd/10.2174/0113816128347041241129055001
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Bellary S. Kyrou I. Brown J.E. Bailey C.J. Type 2 diabetes mellitus in older adults: Clinical considerations and management. Nat. Rev. Endocrinol. 2021 17 9 534 548 10.1038/s41574‑021‑00512‑2 34172940
    [Google Scholar]
  2. Klein S. Gastaldelli A. Yki-Järvinen H. Scherer P.E. Why does obesity cause diabetes? Cell Metab. 2022 34 1 11 20 10.1016/j.cmet.2021.12.012 34986330
    [Google Scholar]
  3. Sinclair A. Saeedi P. Kaundal A. Karuranga S. Malanda B. Williams R. Diabetes and global ageing among 65–99-year-old adults: Findings from the international diabetes federation diabetes atlas, 9th edition. Diabetes Res. Clin. Pract. 2020 162 108078 10.1016/j.diabres.2020.108078 32068097
    [Google Scholar]
  4. Marilly E. Cottin J. Cabrera N. Cornu C. Boussageon R. Moulin P. Lega J.C. Gueyffier F. Cucherat M. Grenet G. SGLT2 inhibitors in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia 2022 65 12 2000 2010 10.1007/s00125‑022‑05773‑8 35925319
    [Google Scholar]
  5. Simes B.C. MacGregor G.G. Sodium-glucose cotransporter-2 (SGLT2) inhibitors: A clinician’s guide. Diabetes Metab. Syndr. Obes. 2019 12 2125 2136 10.2147/DMSO.S212003 31686884
    [Google Scholar]
  6. Neal B. Perkovic V. Mahaffey K.W. de Zeeuw D. Fulcher G. Erondu N. Shaw W. Law G. Desai M. Matthews D.R. CANVAS Program Collaborative Group Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 2017 377 7 644 657 10.1056/NEJMoa1611925 28605608
    [Google Scholar]
  7. Perkovic V. Jardine M.J. Neal B. Bompoint S. Heerspink H.J.L. Charytan D.M. Edwards R. Agarwal R. Bakris G. Bull S. Cannon C.P. Capuano G. Chu P.L. de Zeeuw D. Greene T. Levin A. Pollock C. Wheeler D.C. Yavin Y. Zhang H. Zinman B. Meininger G. Brenner B.M. Mahaffey K.W. CREDENCE Trial Investigators Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260
    [Google Scholar]
  8. Wiviott S.D. Raz I. Bonaca M.P. Mosenzon O. Kato E.T. Cahn A. Silverman M.G. Zelniker T.A. Kuder J.F. Murphy S.A. Bhatt D.L. Leiter L.A. McGuire D.K. Wilding J.P.H. Ruff C.T. Gause-Nilsson I.A.M. Fredriksson M. Johansson P.A. Langkilde A.M. Sabatine M.S. DECLARE–TIMI 58 Investigators Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2019 380 4 347 357 10.1056/NEJMoa1812389 30415602
    [Google Scholar]
  9. Zinman B. Wanner C. Lachin J.M. Fitchett D. Bluhmki E. Hantel S. Mattheus M. Devins T. Johansen O.E. Woerle H.J. Broedl U.C. Inzucchi S.E. EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 2015 373 22 2117 2128 10.1056/NEJMoa1504720 26378978
    [Google Scholar]
  10. Rossing P. Caramori M.L. Chan J.C.N. Heerspink H.J.L. Hurst C. Khunti K. Liew A. Michos E.D. Navaneethan S.D. Olowu W.A. Sadusky T. Tandon N. Tuttle K.R. Wanner C. Wilkens K.G. Zoungas S. Craig J.C. Tunnicliffe D.J. Tonelli M.A. Cheung M. Earley A. de Boer I.H. Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: An update based on rapidly emerging new evidence. Kidney Int. 2022 102 5 990 999 10.1016/j.kint.2022.06.013 36272755
    [Google Scholar]
  11. Fried L.P. Tangen C.M. Walston J. Newman A.B. Hirsch C. Gottdiener J. Seeman T. Tracy R. Kop W.J. Burke G. McBurnie M.A. Cardiovascular Health Study Collaborative Research Group Frailty in older adults: Evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci. 2001 56 3 M146 M157 10.1093/gerona/56.3.M146 11253156
    [Google Scholar]
  12. Cobo A. Vázquez L.A. Reviriego J. Rodríguez-Mañas L. Impact of frailty in older patients with diabetes mellitus: An overview. Endocrinol. Nutr. 2016 63 6 291 303 10.1016/j.endonu.2016.01.004 26971016
    [Google Scholar]
  13. Yoon S.J. Kim K. Frailty and disability in diabetes. Ann. Geriatr. Med. Res. 2019 23 4 165 169 10.4235/agmr.19.0036 32743307
    [Google Scholar]
  14. Wong E. Backholer K. Gearon E. Harding J. Freak-Poli R. Stevenson C. Peeters A. Diabetes and risk of physical disability in adults: A systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2013 1 2 106 114 10.1016/S2213‑8587(13)70046‑9 24622316
    [Google Scholar]
  15. Chen H.L. Hsu W.W.Y. Hsiao F.Y. Changes in prevalence of diabetic complications and associated healthcare costs during a 10-year follow-up period among a nationwide diabetic cohort. J. Diabetes Complications 2015 29 4 523 528 10.1016/j.jdiacomp.2015.02.002 25770886
    [Google Scholar]
  16. O’Donovan M. Sezgin D. O’Caoimh R. Liew A. The impact of and interaction between diabetes and frailty on psychosocial wellbeing and mortality in Ireland. Int. J. Environ. Res. Public Health 2020 17 24 9535 10.3390/ijerph17249535 33352735
    [Google Scholar]
  17. Hickman E. Gillies C. Khunti K. Seidu S. Deprescribing, polypharmacy and prescribing cascades in older people with type 2 diabetes: A focused review. J. Indian Inst. Sci. 2023 103 1 191 204 10.1007/s41745‑022‑00352‑7
    [Google Scholar]
  18. Abdelhafiz A.H. Rodríguez-Mañas L. Morley J.E. Sinclair A.J. Hypoglycemia in older people - A less well recognized risk factor for frailty. Aging Dis. 2015 6 2 156 167 10.14336/AD.2014.0330 25821643
    [Google Scholar]
  19. Baeza-Trinidad R. Mosquera-Lozano J.D. Safety of SGLT2 inhibitors in very elderly diabetic type 2 patients in real life. Iberoam. J. Med. 2023 5 3 118 122 10.53986/ibjm.2023.0023
    [Google Scholar]
  20. Lunati M.E. Cimino V. Gandolfi A. Trevisan M. Montefusco L. Pastore I. Pace C. Betella N. Favacchio G. Bulgheroni M. Bucciarelli L. Massari G. Mascardi C. Girelli A. Morpurgo P.S. Folli F. Luzi L. Mirani M. Pintaudi B. Bertuzzi F. Berra C. Fiorina P. SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. Pharmacol. Res. 2022 183 106396 10.1016/j.phrs.2022.106396 35970329
    [Google Scholar]
  21. Guzmán-Carreras A. Vellisca-González A.M. Molina-Puente J.I. García-Alonso R. Paz-Cabezas M. Sánchez-Sauce B. Aguilar-Rodríguez F. Iguarán-Bermúdez M.D.R. Andrès E. Lorenzo-Villalba N. Méndez-Bailón M. Sodium-glucose cotransporter type 2 inhibitors use in elderly polypathological patients with acute heart failure: PROFUND-IC registry. J. Clin. Med. 2024 13 12 3485 10.3390/jcm13123485 38930015
    [Google Scholar]
  22. CARICO IPLPA. NOTA AIFA 100-Prescrizione degli inibitori del SGLT2, degli agonisti recettoriali del GLP1, degli inibitori del DPP4 e loro associazioni nel trattamento del diabete mellito tipo 2. 2022 Available from: https://www.quotidianosanita.it/allegati/allegato6341242.pdf
  23. ElSayed N.A. Aleppo G. Aroda V.R. Bannuru R.R. Brown F.M. Bruemmer D. Collins B.S. Cusi K. Das S.R. Gibbons C.H. Giurini J.M. Hilliard M.E. Isaacs D. Johnson E.L. Kahan S. Khunti K. Kosiborod M. Leon J. Lyons S.K. Murdock L. Perry M.L. Prahalad P. Pratley R.E. Seley J.J. Stanton R.C. Sun J.K. Woodward C.C. Young-Hyman D. Gabbay R.A. on behalf of the American Diabetes Association Introduction and methodology: Standards of care in diabetes—2023. Diabetes Care 2023 46 Suppl. 1 S1 S4 10.2337/dc23‑Sint 36507647
    [Google Scholar]
  24. Pilotto A. Ferrucci L. Franceschi M. D’Ambrosio L.P. Scarcelli C. Cascavilla L. Paris F. Placentino G. Seripa D. Dallapiccola B. Leandro G. Development and validation of a multidimensional prognostic index for one-year mortality from comprehensive geriatric assessment in hospitalized older patients. Rejuvenation Res. 2008 11 1 151 161 10.1089/rej.2007.0569 18173367
    [Google Scholar]
  25. Pilotto A. Custodero C. Maggi S. Polidori M.C. Veronese N. Ferrucci L. A multidimensional approach to frailty in older people. Ageing Res. Rev. 2020 60 101047 10.1016/j.arr.2020.101047 32171786
    [Google Scholar]
  26. Scheen A.J. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. Diabetes Metab. 2019 45 3 213 223 10.1016/j.diabet.2019.01.008 30708071
    [Google Scholar]
  27. Jasleen B. Vishal G.K. Sameera M. Fahad M. Brendan O.B. Deion S. Pemminati S. Sodium-glucose cotransporter 2 (SGLT2) inhibitors: Benefits versus risk. Cureus 2023 15 1 e33939 10.7759/cureus.33939 36819350
    [Google Scholar]
  28. Chen X. Wang J. Lin Y. Yao K. Xie Y. Zhou T. Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients. Front. Endocrinol. 2023 14 1236404 10.3389/fendo.2023.1236404 38047108
    [Google Scholar]
  29. Fatima A. Rasool S. Devi S. Talha M. Waqar F. Nasir M. Khan M.R. Ibne Ali Jaffari S.M. Haider A. Shah S.U. Sapna F.N.U. Varrassi G. Khatri M. Kumar S. Mohamad T. Exploring the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors: Expanding horizons beyond diabetes management. Cureus 2023 15 9 e46243 10.7759/cureus.46243 37908957
    [Google Scholar]
  30. Shao S.C. Kuo L.T. Chien R.N. Hung M.J. Lai E.C.C. SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: An umbrella review of systematic reviews. BMJ Open Diabetes Res. Care 2020 8 2 e001956 10.1136/bmjdrc‑2020‑001956 33268450
    [Google Scholar]
  31. Zhou P. Tan Y. Hao Z. Xu W. Zhou X. Yu J. Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis. Front. Endocrinol. 2023 14 1144838 10.3389/fendo.2023.1144838 36936142
    [Google Scholar]
  32. Padda I. Mahtani A. Parmar M. Sodium-glucose transport protein 2 (SGLT2) inhibitors. StatPearls. Treasure Island, FL StatPearls Publishing 2024
    [Google Scholar]
  33. Masuda T. Muto S. Fukuda K. Watanabe M. Ohara K. Koepsell H. Vallon V. Nagata D. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin‐induced water reabsorption to maintain body fluid volume. Physiol. Rep. 2020 8 2 e14360 10.14814/phy2.14360 31994353
    [Google Scholar]
  34. Schönberger E. Mihaljević V. Steiner K. Šarić S. Kurevija T. Majnarić L.T. Bilić Ćurčić I. Canecki-Varžić S. Immunomodulatory effects of SGLT2 inhibitors—targeting inflammation and oxidative stress in aging. Int. J. Environ. Res. Public Health 2023 20 17 6671 10.3390/ijerph20176671 37681811
    [Google Scholar]
  35. Chilton R. Tikkanen I. Cannon C.P. Crowe S. Woerle H.J. Broedl U.C. Johansen O.E. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes. Metab. 2015 17 12 1180 1193 10.1111/dom.12572 26343814
    [Google Scholar]
  36. Li H. Shin S.E. Seo M.S. An J.R. Choi I.W. Jung W.K. Firth A.L. Lee D.S. Yim M.J. Choi G. Lee J.M. Na S.H. Park W.S. The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels. Life Sci. 2018 197 46 55 10.1016/j.lfs.2018.01.032 29409796
    [Google Scholar]
  37. Erdem S. Titus A. Patel D. Patel N.N. Sattar Y. Glazier J. Alraies C.M. Sodium-glucose cotransporter 2 inhibitors: A scoping review of the positive implications on cardiovascular and renal health and dynamics for clinical practice. Cureus 2023 15 4 e37310 10.7759/cureus.37310 37182087
    [Google Scholar]
  38. Januzzi J.L. Jr Butler J. Jarolim P. Sattar N. Vijapurkar U. Desai M. Davies M.J. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J. Am. Coll. Cardiol. 2017 70 6 704 712 10.1016/j.jacc.2017.06.016 28619659
    [Google Scholar]
  39. Bellary S. Barnett A.H. SGLT2 inhibitors in older adults: Overcoming the age barrier. Lancet Healthy Longev. 2023 4 4 e127 e128 10.1016/S2666‑7568(23)00039‑9 37003269
    [Google Scholar]
  40. Scheen A.J. Bonnet F. Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance? Diabetes Metab. 2023 49 2 101419 10.1016/j.diabet.2023.101419 36640828
    [Google Scholar]
  41. Aldafas R. Crabtree T. Alkharaiji M. Vinogradova Y. Idris I. Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: A systematic review and meta-analysis. Age Ageing 2024 53 1 afad254 10.1093/ageing/afad254 38287703
    [Google Scholar]
  42. Mone P. Varzideh F. Jankauskas S.S. Pansini A. Lombardi A. Frullone S. Santulli G. SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: Insights from frail hypertensive and diabetic patients. Hypertension 2022 79 8 1633 1643 10.1161/HYPERTENSIONAHA.122.19586 35703100
    [Google Scholar]
  43. Vart P Butt JH Jongs N Schechter M Chertow GM Wheeler DC Efficacy and safety of dapagliflozin in patients with chronic kidney disease across the spectrum of frailty. J. Gerontol. A. 2024 79 2 glad181 10.1093/gerona/glad181
    [Google Scholar]
  44. Cruz-Jentoft A.J. Baeyens J.P. Bauer J.M. Boirie Y. Cederholm T. Landi F. Martin F.C. Michel J.P. Rolland Y. Schneider S.M. Topinková E. Vandewoude M. Zamboni M. European Working Group on Sarcopenia in Older People Sarcopenia: European consensus on definition and diagnosis. Age Ageing 2010 39 4 412 423 10.1093/ageing/afq034 20392703
    [Google Scholar]
  45. Atiénzar P. Abizanda P. Guppy A. Sinclair A.J. Diabetes and frailty: An emerging issue. Part 2: Linking factors. Br. J. Diabetes Vasc. Dis. 2012 12 3 119 122 10.1177/1474651412450304
    [Google Scholar]
  46. Morley J.E. Diabetes, sarcopenia, and frailty. Clin. Geriatr. Med. 2008 24 3 455 469, vi 10.1016/j.cger.2008.03.004 18672182
    [Google Scholar]
  47. Morley J.E. Kim M.J. Haren M.T. Frailty and hormones. Rev. Endocr. Metab. Disord. 2005 6 2 101 108 10.1007/s11154‑005‑6722‑9 15843881
    [Google Scholar]
  48. Kalyani R.R. Corriere M. Ferrucci L. Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol. 2014 2 10 819 829 10.1016/S2213‑8587(14)70034‑8 24731660
    [Google Scholar]
  49. Kim J. Wei Y. Sowers J.R. Role of mitochondrial dysfunction in insulin resistance. Circ. Res. 2008 102 4 401 414 10.1161/CIRCRESAHA.107.165472 18309108
    [Google Scholar]
  50. Malik M.E. Butt J.H. Strange J.E. Falkentoft A.C. Jensen J. Andersson C. Zahir D. Fosbøl E. Petrie M.C. Sattar N. McMurray J.J.V. Køber L. Schou M. Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: A cross-sectional, nationwide study. Lancet Healthy Longev. 2023 4 10 e552 e560 10.1016/S2666‑7568(23)00164‑2 37734395
    [Google Scholar]
  51. Ng N.M. Ng Y.S. Chu T.K. Lau P. Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: A qualitative study. BMC Prim. Care 2022 23 1 317 10.1186/s12875‑022‑01928‑z 36476327
    [Google Scholar]
  52. Kehoe R. Wu S.Y. Leske M.C. Chylack L.T. Jr Comparing self-reported and physician-reported medical history. Am. J. Epidemiol. 1994 139 8 813 818 10.1093/oxfordjournals.aje.a117078 8178794
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128347041241129055001
Loading
Use of SGLT2 Inhibitors in Frail Older Adults is Associated with Increased Survival: A Retrospective Study
Bentham Science Publishers ; https://doi.org/10.2174/0113816128347041241129055001
/content/journals/cpd/10.2174/0113816128347041241129055001
/content/journals/cpd/10.2174/0113816128347041241129055001
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: SGLT2 inhibitors ; Diabetes ; aging ; mortality ; frailty

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test